Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
复制标题
DOI：
10.1517/13543784.2011.542147
复制
发表时间：
2011-01-01
影响因子：
6.1
通讯作者：
Ansell, Stephen M.
中科院分区：
文献类型：
--
作者：
Ansell, Stephen M.
该领域的重要性：复发或难治性cd30阳性淋巴增生性疾病（如霍奇金淋巴瘤（HL）和间变性大细胞淋巴瘤（ALCL））的患者通常预后较差。具有这些组织学的患者在补救性化疗和自体干细胞移植（ASCT）后病情恶化，治疗选择非常有限，需要新的有效治疗方法。本综述涵盖的领域：基于已发表的文献和可获得的摘要，本综述描述了cd30导向抗体-药物偶联物brentuximab vedotin （SGN-35）的发展，该药物在HL和ALCL模型中的临床前活性，以及初步临床试验的结果。读者将获得什么：这篇综述讨论了使用CD30靶向递送抗有丝分裂药物的效用，该方法的安全性和活性，以及将该疗法整合到当前治疗组合中的潜在未来前景和挑战。综上所述：在回顾brentuximab vedotin治疗复发性HL和ALCL的初步结果时，brentuximab vedotin似乎具有良好的耐受性，并且在CD30（+）淋巴瘤中具有良好的活性。
Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies.Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibody-drug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials.What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations.Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30(+) lymphomas.